Preliminary results from a study examining the efficacy of the Oxford-AstraZeneca coronavirus vaccine indicate it is significantly effective at preventing severe illness from COVID-19.
Results of the trial, which involved more than 32,000 volunteers, showed two doses of the vaccine administered four weeks apart had an efficacy of 79% at preventing symptoms of COVID-19. In participants aged 65 years and over, vaccine efficacy could be as high as 80%, AstraZeneca announced early Monday. It had an efficacy of 100% at preventing severe disease and hospitalization.
